艾德生物
(300685)
| 流通市值：82.22亿 | | | 总市值：82.95亿 |
| 流通股本：3.95亿 | | | 总股本：3.98亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 847,967,831.38 | 543,017,402.22 | 233,288,808.06 | 1,043,506,694.32 |
| 营业收入 | 847,967,831.38 | 543,017,402.22 | 233,288,808.06 | 1,043,506,694.32 |
| 二、营业总成本 | 596,597,050.32 | 383,540,305.43 | 167,788,210.58 | 743,673,780.47 |
| 营业成本 | 129,440,425.59 | 80,621,369.42 | 36,257,584.57 | 167,293,960.37 |
| 税金及附加 | 3,704,087.49 | 2,556,098.98 | 791,514.8 | 4,671,686.63 |
| 销售费用 | 252,002,610.11 | 160,378,604.52 | 65,440,315.27 | 329,493,879.54 |
| 管理费用 | 58,257,058.21 | 44,033,803.71 | 20,199,068.62 | 64,846,632.32 |
| 研发费用 | 164,361,893.33 | 106,212,012.43 | 48,363,080.43 | 203,217,283.53 |
| 财务费用 | -11,169,024.4 | -10,261,583.63 | -3,263,353.11 | -25,849,661.92 |
| 其中:利息费用 | 906,160.56 | 508,587.68 | 306,922.67 | 1,195,078.85 |
| 其中:利息收入 | 19,560,759.61 | 12,836,353.81 | 6,135,144 | 19,169,576.79 |
| 加:公允价值变动收益 | 6,409,871.62 | 4,637,822.22 | 2,616,462.72 | 8,394,360.75 |
| 加:投资收益 | -229,685.66 | 499,365.75 | -220,268.16 | -10,393,975.1 |
| 资产处置收益 | 15,576.72 | 7,064.41 | 50,535.06 | -959,584.98 |
| 资产减值损失(新) | -7,967,978.99 | -7,959,455.81 | 5,008.05 | -13,524,302.99 |
| 信用减值损失(新) | -7,794,373.01 | -5,454,971.33 | 775,665.58 | -5,315,987.25 |
| 其他收益 | 11,399,317.93 | 8,963,678.72 | 6,219,563.96 | 23,213,292.59 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 253,203,509.67 | 160,170,600.75 | 74,947,564.69 | 301,246,716.87 |
| 加:营业外收入 | 45,576.79 | 41,025.79 | 34,048.01 | 123,031.32 |
| 减:营业外支出 | 2,142,440.55 | 1,787,533.71 | 1,415,388.36 | 6,512,623.63 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 251,106,645.91 | 158,424,092.83 | 73,566,224.34 | 294,857,124.56 |
| 减:所得税费用 | 23,836,108.42 | 14,567,526.82 | 9,367,156.31 | 33,372,691.19 |
| 六、净利润 | 227,270,537.49 | 143,856,566.01 | 64,199,068.03 | 261,484,433.37 |
| 持续经营净利润 | 227,270,537.49 | 143,856,566.01 | 64,199,068.03 | 261,484,433.37 |
| 归属于母公司股东的净利润 | 227,270,537.49 | 143,856,566.01 | 64,199,068.03 | 261,484,433.37 |
| (一)基本每股收益 | 0.57 | 0.36 | 0.16 | 0.66 |
| (二)稀释每股收益 | 0.57 | 0.36 | 0.16 | 0.66 |
| 八、其他综合收益 | 56,809.94 | -553,194.26 | - | 602,856.41 |
| 归属于母公司股东的其他综合收益 | 56,809.94 | -553,194.26 | - | 602,856.41 |
| 九、综合收益总额 | 227,327,347.43 | 143,303,371.75 | 64,199,068.03 | 262,087,289.78 |
| 归属于母公司股东的综合收益总额 | 227,327,347.43 | 143,303,371.75 | 64,199,068.03 | 262,087,289.78 |
| 公告日期 | 2024-10-22 | 2024-07-30 | 2024-04-23 | 2024-04-16 |
| 审计意见(境内) | | | | 标准无保留意见 |